Study on Prognosis of Acute-on-chronic Liver Failure Complicated by Bacterial or Fungal Infection

Launched by QIN NING · May 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at patients who have a serious condition called Acute-on-Chronic Liver Failure (ACLF) and are dealing with bacterial or fungal infections. The study is taking place at Tongji Hospital in Wuhan and will run from March 2023 to June 2025. It aims to understand how these infections affect the health and recovery of patients with ACLF. Researchers will gather information about the patients, such as their age, gender, medical history, symptoms, and results from various tests. They will also separate patients into groups based on whether they have a bacterial infection, a fungal infection, or no infection at all.

To participate in this trial, patients need to be between 18 and 80 years old, have chronic hepatitis B, and show certain laboratory test results indicating liver issues. Unfortunately, those with other severe health problems, pregnancy, or incomplete medical information cannot take part. Patients who join the study can expect to be closely monitored over several weeks and will help researchers learn more about how infections impact those with liver problems, ultimately aiming to improve future treatment and care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. TBIL ≥ 12 mg/mL and INR ≥ 1.5
• • 2. Chronic hepatitis B
• Exclusion Criteria:
• • (1) \<18 or \>80 years old; (2) primary hepatic or extrahepatic carcinoma; (3) with severe diseases of other organs or systems; (4) pregnancy; (5) imcomplete information